Lilly Asia Ventures achieved an exit in a Hong Kong offering in which the oncology therapy developer floated at the top of its range.
Jacobio Pharmaceuticals, a China-based cancer, autoimmune and infectious diseases drug developer backed by pharmaceutical firm Eli Lilly, has floated in a $174m initial public offering, DealStreetAsia has reported. The company issued almost 96.5 million shares on the Hong Kong Stock Exchange priced at HK$14.00 ($1.81) each, at the top of the IPO’s HK$12 to HK$14…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.